Pharmacology

New to The Street Announces its Televised Five Corporate Interviews, Episodes 547 and 548, Show Airs as Sponsored Programming on Bloomberg TV and the FOX Business Network; Broadcastings Begin on Saturday, January 13, 2024, at 6:30 PM ET

Retrieved on: 
Friday, January 12, 2024

New to The Street show airs on Bloomberg TV as a sponsored programming Saturday, January 13, 2024, at 6:30 PM ET; features the following five (5) corporate interviews:

Key Points: 
  • New to The Street show airs on Bloomberg TV as a sponsored programming Saturday, January 13, 2024, at 6:30 PM ET; features the following five (5) corporate interviews:
    1).
  • New to The Street show airs on the FOX Business Network on Monday, January 15, 2024, at 10:30 PM PT; features the following five (5) corporate interviews:
    1).
  • Air Travel Electrification – Surf Air Mobility, Inc.'s (NYSE: SRFM) ($SRFM) interviews with Stan Little, Chief Executive Officer, and Sudhin Shahani, Founder .
  • The interview will air on Bloomberg TV as sponsored programming on Saturday, January 13, 2024, at 6:30 PM ET.

Enveda Biosciences Announces Therapeutic Advisory Board Chaired by Nicholas Saccomano, Ph.D.

Retrieved on: 
Wednesday, January 10, 2024

Enveda Biosciences, a biotechnology company using AI and advanced technologies to translate nature’s chemistry into new medicines, today announced the formation of a Therapeutic Advisory Board (TAB), chaired by Nicholas Saccomano, Ph.D.

Key Points: 
  • Enveda Biosciences, a biotechnology company using AI and advanced technologies to translate nature’s chemistry into new medicines, today announced the formation of a Therapeutic Advisory Board (TAB), chaired by Nicholas Saccomano, Ph.D.
  • “This is an incredibly exciting time for Enveda as we launch our first trials for multiple lead assets and transition into a clinical-stage company.
  • The formation of the TAB marks a significant milestone for Enveda Biosciences as they advance their first assets for a range of inflammatory and neurosensory conditions.
  • Founded in 2019, the company plans to launch at least two clinical trials in 2024.

PumasAI Maintains Strong Growth Trajectory with New Product Engineering and Pharmacometrics Hires from JuliaHub and Pfizer

Retrieved on: 
Friday, January 12, 2024

DOVER, Del., Jan. 12, 2024 /PRNewswire-PRWeb/ -- PumasAI, a pioneering organization at the forefront of transforming data into life-saving decisions with remarkable speed, is proud to announce the appointment of two distinguished leaders to its team.

Key Points: 
  • Dr. Andreas Noack, a luminary in product engineering, joins PumasAI as the Head of Product Engineering, and Dr. Jessica Wojciechowski, an esteemed expert in clinical pharmacology and pharmacometrics, will be joining the team as the Director of Clinical Pharmacology and Pharmacometrics.
  • - Dr. Vijay Ivaturi, CEO, PumasAI
    Dr. Andreas Noack, a luminary in product engineering, joins PumasAI as the Head of Product Engineering.
  • Dr. Jessica Wojciechowski, an esteemed expert in clinical pharmacology and pharmacometrics, will be joining the team as the Director of Clinical Pharmacology and Pharmacometrics.
  • Based in Connecticut, Dr. Wojciechowski transitions to PumasAI from Pfizer, where she held the pivotal role of Director of Pharmacometrics.

ACCP Position Statement: "Inclusion of Obese Participants in Drug Development: Reflections on the Current Landscape and a Call for Action"

Retrieved on: 
Thursday, January 11, 2024

ASHBURN, Va., Jan. 11, 2024 /PRNewswire/ -- A recent Position Paper from the American College of Clinical Pharmacology® (ACCP) entitled " Inclusion of Obese Participants in Drug Development: Reflections on the Current Landscape and a Call for Action" was published in The Journal of Clinical Pharmacology.

Key Points: 
  • ASHBURN, Va., Jan. 11, 2024 /PRNewswire/ -- A recent Position Paper from the American College of Clinical Pharmacology® (ACCP) entitled " Inclusion of Obese Participants in Drug Development: Reflections on the Current Landscape and a Call for Action" was published in The Journal of Clinical Pharmacology.
  • Obesity is a national health issue, with a prevalence that has increased steadily in the United States over the past 20 years.
  • This is a concern, as obesity is associated with an increased risk for many other comorbid diseases.
  • This Position Paper calls for actions to enable the inclusion of obese participants in clinical trials during the drug development process.

National Korea Maritime and Ocean University Researchers Explore the Impact of Microplastics and Toxin Exposure on Goldfish

Retrieved on: 
Thursday, January 11, 2024

The presence of microplastics, ranging in size from 100 nanometers to 5 millimeters, is particularly concerning.

Key Points: 
  • The presence of microplastics, ranging in size from 100 nanometers to 5 millimeters, is particularly concerning.
  • Another aspect of microplastic pollution, often overlooked but equally dangerous, is their ability to absorb and carry harmful chemicals, such as persistent organic pollutants.
  • Understanding the extent of toxicity and threat posed by the combined impact of exposure to microplastics and other pollutants is, therefore, important.
  • In a recent study now, researchers led by Dr. Cheol Young Choi from National Korea Maritime and Ocean University explored the impact of microplastic and BaP exposure on freshwater goldfish (Carassius auratus), who were exposed to BaP and microplastics individually and in combination, to understand their exposure effects.

C-Path Appoints Dr. Klaus Romero as New CEO

Retrieved on: 
Tuesday, January 9, 2024

TUCSON, Ariz., Jan. 9, 2024 /PRNewswire/ -- Critical Path Institute (C-Path) today announced that Klaus Romero, M.D., M.S., FCP, has been named its new Chief Executive Officer. Romero, a seasoned clinician scientist, has been vital in positioning C-Path as an essential partner in accelerating drug development worldwide, significantly shaping scientific and regulatory pathways to expedite the delivery of therapies for people in urgent need.

Key Points: 
  • TUCSON, Ariz., Jan. 9, 2024 /PRNewswire/ -- Critical Path Institute (C-Path) today announced that Klaus Romero, M.D., M.S., FCP, has been named its new Chief Executive Officer.
  • "Assuming the position of CEO at C-Path represents a profound honor, coupled with a tremendous sense of responsibility," said Romero.
  • His ascension to CEO is a significant milestone in our mission to bring transformative therapies to patients who desperately need them."
  • Romero will continue to serve a dual role as CEO and CSO until the CSO position is filled.

PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance

Retrieved on: 
Monday, January 8, 2024

“The dawn of MDMA as a therapeutic molecule is just beginning, and while we are actively working to treat patients with that molecule, we are also looking towards a future with novel molecular assets,” said Nick Kadysh, CEO, PharmAla Biotech.

Key Points: 
  • “The dawn of MDMA as a therapeutic molecule is just beginning, and while we are actively working to treat patients with that molecule, we are also looking towards a future with novel molecular assets,” said Nick Kadysh, CEO, PharmAla Biotech.
  • “P-1 is one of a number of next-generation assets which we are developing, and which promise to bring together both increased safety, and highly beneficial effects like increased neuroplasticity.”
    The Patent Prosecution Highway (PPH) speeds up the examination process for corresponding applications filed in participating intellectual property offices.
  • Under PPH, participating patent offices have agreed that when an applicant receives a ruling from a first patent office indicating that at least one claim is allowable, the applicant may request fast track examination of corresponding claims.
  • Proof-of-concept testing for P-1 showed significant efficacy and pro-social effect at dosage levels far lower than MDMA, PharmAla’s primary comparator molecule, as well as excellent safety pharmacology.

Rice Biotech Launch Pad adds pharmaceuticals pioneer Robert Ruffolo to external advisory board

Retrieved on: 
Monday, January 8, 2024

HOUSTON, Jan. 8, 2024 /PRNewswire/ -- Rice University today announced the addition of Robert Ruffolo Jr. to its external advisory board for the Rice Biotech Launch Pad , a Houston-based accelerator focused on expediting the translation of the university's health and medical technology discoveries into cures.

Key Points: 
  • HOUSTON, Jan. 8, 2024 /PRNewswire/ -- Rice University today announced the addition of Robert Ruffolo Jr. to its external advisory board for the Rice Biotech Launch Pad , a Houston-based accelerator focused on expediting the translation of the university's health and medical technology discoveries into cures.
  • "Dr. Ruffolo brings immense value to the Rice Biotech Launch Pad as an adviser to drive drug development," said Omid Veiseh , associate professor of bioengineering at Rice and faculty director of the Launch Pad.
  • "The Rice Biotech Launch Pad is one of the most forward-looking and technologically innovative teams in the drug development space right now," Ruffolo said.
  • Ruffolo is the 13th member of the Launch Pad's external advisory board.

Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims

Retrieved on: 
Monday, January 8, 2024

11,826,327 (the ‘327 patent) in association with Liquidia’s New Drug Application (NDA) for YUTREPIA™ (treprostinil) inhalation powder.

Key Points: 
  • 11,826,327 (the ‘327 patent) in association with Liquidia’s New Drug Application (NDA) for YUTREPIA™ (treprostinil) inhalation powder.
  • Simultaneously, Liquidia filed counterclaims against UTHR seeking a declaration that all asserted claims of the ‘327 patent are not infringed, are invalid and are unenforceable.
  • Furthermore, the counterclaims summarize certain publications, references and information that UTHR failed to submit to the United States Patent and Trademark Office (USPTO) during the prosecution of the ‘327 patent.
  • Liquidia has also asserted that these same references and information, as set forth in the counterclaims, also render the claims of the ‘327 patent invalid.

CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook

Retrieved on: 
Monday, January 8, 2024

ZUG, Switzerland and BOSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and 2024 outlook as the Company enters its next phase of growth.

Key Points: 
  • ZUG, Switzerland and BOSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and 2024 outlook as the Company enters its next phase of growth.
  • Exa-cel is the first therapy to emerge from a strategic partnership between CRISPR Therapeutics and Vertex Pharmaceuticals.
  • Vertex leads global development, manufacturing, regulatory and commercialization of CASGEVY with support from CRISPR Therapeutics.
  • CRISPR Therapeutics continues to focus on resource efficiency and return on invested capital as it advances multiple clinical programs across its pipeline.